MSB

10.4%

$1.49 mesoblast limited

Attention: Dr. Silviu Itescu, page-41

First 41 Last

Share
Profile

Follow
vasilios

3,890 Posts.

362

03/01/21

12:19

Post #: 49910927
Share

Originally posted by Pledge: ↑

major shareholders will decide SI fate.

All shareholders (major and minor) will do that. Major shareholders carry more weight of course. Major shareholders wouldn't like where the share price is! Major shareholders won't like being promised an important milestone and given silence instead. There are shareholders (like you) that love it though, apparently.

if they had no confidence in him, he would of been gone a long time ago.

The Peter Principle. Look it up. Are you so blinded that you cannot fathom that a person can be useful and people have confidence in them yesterday (then they act in a certain way) then not tomorrow? Is that love in the air?

Basically, I don't give a rats arse how the announcements are written or why he hasn't told as the results of the A type meeting on agvhd (we know it's unlikely fda will approve) or why certain timelines stated haven't eventuate.

I never mentioned anything outside of the written and verbal promise by SI on the 24th Nov 2020 to deliver the CLP results by quarter 4 2020 (which was at the time about 5 weeks later). I assume as a shareholder you care about the share price or are you that far removed from reality?

The reason why, is because I understand the current results of each trial to date and the complexity of stem cells.

SI is learning about trials and stem cells as the trials unfold (and finding out things that were not realised prior to the trials) yet you have your head around it all? Sure.

SI needs not to elaborate any further.

Yes, he does. You are showing your naivety again.

if you're not happy with management that is justification to sell and move on.

Gee, thanks. I'm invested to make money and I think there is money to be made here. Although I understand that others that are invested here do so for the betterment of man and other higher purposes. I am a 'dirty' investor and others are 'lily white' investors. Ha ha ha. Management are struggling here. Blind Freddy can see that changes in management are on the horizon. I believe that management have to be held responsible - you believe they can do what they want and should be given unconditional love? One of us is off their head? I'll act surprised when changes in management occur in the next few weeks.

As you know, management is the key to a successful business.

It's a double edged sword. Management are effecting the share price in a negative way through their action/inaction. I don't like it and I want it to stop. You think it's great.

This is a forum to discuss MSB, not a 'who loves MSB more' competition.

And with that, I am at an end of our communications. Best of British luck.

Expand

I said I understand the trial results! please read my post carefully.

MSB Price at posting: $2.25 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

BUX

Buxton projects new graphite province discovery at WA Narryer play

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 3 more messages in this thread...

First 41 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.49		Change 0.140(10.4%)		Mkt cap ! $1.701B

Open	High	Low	Value	Volume
$1.37	$1.54	$1.37	$23.10M	15.82M

Buyers (Bids)

No.	Vol.	Price($)
3	24758	$1.49

Sellers (Offers)

Price($)	Vol.	No.
$1.49	73626	3

View Market Depth

No.	Vol.	Price($)
1	10033	1.485
4	53700	1.480
1	770	1.475
3	62048	1.460
1	50000	1.455

Price($)	Vol.	No.
1.490	21995	1
1.505	24000	1
1.510	13666	2
1.515	99798	1
1.520	27250	3

Last trade - 16.10pm 04/10/2024 (20 minute delay)

MSB (ASX) Chart

Attention: Dr. Silviu Itescu, page-41

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Buxton projects new graphite province discovery at WA Narryer play

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Attention: Dr. Silviu Itescu, page-41

Top Stories

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Buxton projects new graphite province discovery at WA Narryer play

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News